Antibody-conjugate Mediated Degradation
Antibody conjugate-mediated degradation (AbTACs or PROTAbs) represents yet another innovative approach to targeted protein degradation. By coupling antibodies specific to cell surface proteins with molecules that induce degradation, this technique enables precise elimination of disease-causing proteins. Offering a potent and highly specific therapeutic strategy, antibody conjugate-mediated degradation holds promise for treating a wide range of diseases with aberrant protein expression, including cancer and neurodegenerative disorders.
AbTACs/PROTAbs consist of two components in a Bispecific Antibody:
✅ E3 ligase recruiter Antibody
✅ Target protein binding Antibody
Lifesensors offers unique and physiologically relevant target ubiquitination and degradation assays that allows rapid characterization of AbTACs/PROTAbs for their specificity and potency.
LifeSensors helps you study the AbTACs/PROTAbs to make breakthrough discoveries and pave the way to novel therapeutics.
Advantages of Choosing LifeSensors for your PROTAC Drug Discovery
- Study PROTAC mediated Ubiquitination and Degradation simultaneously
- Complete suite of validation studies to establish binding, ternary complex formation, and cellular degradation
- Experience with novel E3 ligases – ~30 E3 ligases amenable to PROTAC discovery
- Proteomics to characterize protein degradation – establish selectivity